In a collaboration with Novartis, we (SciCross) has developed a method for improved HLA class II binding prediction based on MAPPs data. The results till be presented at the Immunogenicity and Bioassay Summit (https://www.immunogenicitysummit.com/), which in 2020 will be hosted as a virtual conference. And yes, the performance accuracy of the methods is great!
New paper published in Lancet Rheumatology on immune cell signatures in JSLE patients, discovered by machine learning techniques AND extensive laboratory work AND clinical knowledge. Really happy to have the privilege to collaborate with this amazing group of people!
#Machinelearning #AI #UCL #JSLE
SciCross partners with scientists from Uppsala University, KTH and SciLifeLab in developing Covid-19 treatments in immune suppressed individuals. The project is called “An adaptable therapeutic technology platform to treat SARS-CoV infections in immune suppressed individuals” and has received funding from SciLifeLab and Knut and Alice Wallenberg Foundation (https://kaw.wallenberg.org/). SciCross focus will be on identifying parts in the SARS-CoV-2 genome that can elicit an immune response towards the virus. More details about the project will follow soon.
Great news before Christmas. SciCross is part of a project receiving funding from the Swedish Knowledge Foundation. The project title is “Biomedical AI-driven data analytics” (BIO-AID) and will start in 2020. The project will focus on how AI/Machine learning approaches can be designed and applied in Life Science. Coordinated by the University of Skövde, other project members include Merck, Takarabio, MultiD and TATAA Biocenter.
Read more at: https://www.mynewsdesk.com/se/his/pressreleases/miljonregn-oever-projekt-paa-hoegskolan-i-skoevde-2954981 (Swedish only)
In a recent paper written with colleagues from the ABIRISK consortium we present a study of the genetic risk associated with inhibitor development in patients with severe hemophilia A. #ABIRISK #immunogenicity
A recent paper originating from ABIRISK research has been made available online. The paper presents an analysis of retrospective data in European cohort of RA patients treated with adalimumab or infliximab.
The paper with title “Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis” has been published in Seminars in Arthritis and Rheumatism:https://www.sciencedirect.com/science/article/pii/S0049017218301768
A better understanding of the blood-brain barrier (BBB) is key for developing treatments for disease like MS and Alzheimer’s. In a collaboration with AstraZeneca, KTH, Karolinska Institute and University of Skövde we recently published an article studying the use of human stem cells to generate in vitro models of the BBB. More specifically, we studied the barrier properties and transcriptome of iPSC-derived models. Check out the full article published in Stem Cells (pubmed).
Paper describing the effect of Methotrexate and BAFF levels during TNF inhibitor treatment in RA patients. Work done within the ABIRISK project with SciCross contributing in the managements of clinical data and data analysis. Check out the full paper at: https://ard.bmj.com/content/77/10/1463.long
In a recent paper, published in Journal of Clinical Investigation Insight, we describe a number of factors that influence the risk of immunogenicity responses (anti drug antibodies, ADA) in Multiple Sclerosis patients treated with Interferon beta (IFN-β). We found that NOTCH2 expression on CD14+ cells and increased frequency of proinflammatory monocyte subsets can be used as baseline predictors of neutralizing ADA (nADA) in MS patients treated with IFN-β. Further investigation of NOTCH2 showed that nADA development was driven by a proinflammatory environment that triggered activation of the NOTCH2 signaling pathway prior to first IFN-β administration.
Check out the full paper.
In a collaboration with the University of Tübingen and Harvard Medical School we have published a paper on how to reduce immunogenicity and at the same time keep protein stability/function. The approach is based on multi-objective combinatorial optimisation and was tested on the C2 domain of Factor VIII. For the full paper, go to Population-specific design of de-immunized protein biotherapeutics.